Third Quarter 2017 Results

Bayer AG News Conference Call

Third quarter of 2017:

Bayer: Sales and earnings increased

  • Covestro deconsolidated
  • Group sales grow by 1.2 percent (Fx & portfolio adj.) to EUR 8,025 million
  • EBITDA before special items up by 4.1 percent to EUR 2,204 million
  • Sales and earnings growth at Pharmaceuticals
  • Consumer Health business weak, as expected
  • Sales gains at Crop Science and Animal Health
  • Net income of EUR 3,881 million including Covestro book profit
  • Core earnings per share at EUR 1.47 (minus 3.9 percent)
  • Group outlook for 2017 confirmed based on change in structure
    » more



Werner Baumann

Werner Baumann
CEO of Bayer AG

Follow the coverage in our social media channel:


You will find the key statements on » Twitter